The board


Tormod Fladby

Fladby is Professor at the Department of Clinical Medicine (UiO) and Akershus University Hospital. He researching on pre-dementia and early diagnosis of dementia.




Board Members

Håkon Sæterøy

Sæterøy is Managing Director of INVESTOR Corporate AS, CEO of Pre Diagnostics and Senior Corporate Finance Advisor with VL Corporate AS. He was Chairman of NNN from 2010 – 2012 and Chairman of DiaGenic ASA from 2002 – 2010. Sæterøy is a board member of Oslo Cancer Cluster and shareholder and board member of several life science companies in Norway. He has a Master of Science in Business from NHH in Bergen, and more than 25 years of experience within Corporate Finance.


Leif Rune Skymoen

Skymoen is former CEO of NNN and now CEO of the Norwegian Contract and Development Manufacturing Organization, Curida. 


Pål Richard Romundstad

Romundstad is the Vice Dean for Research at the Faculty of Medicine and Professor of Epidemiology at the Department of Public Health and General Practice at NTNU (Norwegian University of Science and Technology)



Beatrix Vereijken

 Professor, Department of Neuroscience at NTNU



Anne Rita Øksengård

Dr. Med. Head of research, the National Association
for Public Health




Jens Halvard Grønlien

Medical Affairs Manager at AbbVie


Anders Fuggeli

CEO of Pharmasum Therapeutics
Anders Fugelli is Co-founder of Pharmasum Therapeutics. He has a passion for brain diseases, with more than 20 years experience in academia and industrial R&D.



Johanne Egge Rinholm

Post Doc, University of Oslo

Rinholm has worked at Nansen Neuroscience Network as a Project Associate.


Jonny Østensen

Vice President Technology in Inven2
Inven2 is the next-generation innovation company, established to maintain and develop Norwegian innovations. It is the largest contributor in Norway within the field of commercialization of research, owned by the University of Oslo and Oslo University Hospital, Norway's largest and leading university and hospital representing pioneering research